Literature DB >> 19209850

Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.

Ravi Rajagopalan1, Shawn Misialek, Sarah K Stevens, David G Myszka, Barbara J Brandhuber, Joshua A Ballard, Steven W Andrews, Scott D Seiwert, Karl Kossen.   

Abstract

The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication. ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral load reductions in chronic HCV patients. Here, ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism. Progress curves are consistent with the formation of an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissociates very slowly. K(i), the dissociation constant of EI, is 100 nM, and the rate constant for conversion of EI to EI* is 6.2 x 10(-2) s(-1). Binding experiments using protein fluorescence confirm this isomerization rate. From progress curve analysis, the rate constant for dissociation of ITMN-191 from the EI* complex is 3.8 x 10(-5) s(-1) with a calculated complex half-life of approximately 5 h and a true biochemical potency (K(i)*) of approximately 62 pM. Surface plasmon resonance studies and assessment of enzyme reactivation following dilution of the EI* complex confirm slow dissociation and suggest that the half-life may be considerably longer. Abrogation of the tight binding and slow dissociative properties of ITMN-191 is observed with proteases that carry the R155K or D168A substitution, each of which is likely in drug resistant mutants. Slow dissociation is not observed with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19209850     DOI: 10.1021/bi900038p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

Review 2.  Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target.

Authors:  Kevin D Raney; Suresh D Sharma; Ibrahim M Moustafa; Craig E Cameron
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

3.  Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

Authors:  Michael T Rudd; John A McCauley; John W Butcher; Joseph J Romano; Charles J McIntyre; Kevin T Nguyen; Kevin F Gilbert; Kimberly J Bush; M Katharine Holloway; John Swestock; Bang-Lin Wan; Steven S Carroll; Jillian M DiMuzio; Donald J Graham; Steven W Ludmerer; Mark W Stahlhut; Christine M Fandozzi; Nicole Trainor; David B Olsen; Joseph P Vacca; Nigel J Liverton
Journal:  ACS Med Chem Lett       Date:  2011-01-12       Impact factor: 4.345

4.  A [(32)P]NAD(+)-based method to identify and quantitate long residence time enoyl-acyl carrier protein reductase inhibitors.

Authors:  Weixuan Yu; Carla Neckles; Andrew Chang; Gopal Reddy Bommineni; Lauren Spagnuolo; Zhuo Zhang; Nina Liu; Christina Lai; James Truglio; Peter J Tonge
Journal:  Anal Biochem       Date:  2015-02-14       Impact factor: 3.365

5.  Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.

Authors:  Ravi Rajagopalan; Lin Pan; Caralee Schaefer; John Nicholas; Sharlene Lim; Shawn Misialek; Sarah Stevens; Lisa Hooi; Natalia Aleskovski; Donald Ruhrmund; Karl Kossen; Lea Huang; Sophia Yap; Leonid Beigelman; Vladimir Serebryany; Jyanwei Liu; Srikonda Sastry; Scott Seiwert; Brad Buckman
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.

Authors:  Andrew Bae; Siu-Chi Sun; Xiaoping Qi; Xiaowu Chen; Karin Ku; Angela Worth; Kelly A Wong; Jeanette Harris; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

7.  Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Authors:  X Tong; A Arasappan; F Bennett; R Chase; B Feld; Z Guo; A Hart; V Madison; B Malcolm; J Pichardo; A Prongay; R Ralston; A Skelton; E Xia; R Zhang; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 8.  Drug-target residence time: critical information for lead optimization.

Authors:  Hao Lu; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2010-07-19       Impact factor: 8.822

9.  A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

Authors:  Peter N Morcos; Linda Chang; Rohit Kulkarni; Mylene Giraudon; Nancy Shulman; Barbara J Brennan; Patrick F Smith; Jonathan Q Tran
Journal:  Eur J Clin Pharmacol       Date:  2013-07-20       Impact factor: 2.953

10.  Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

Authors:  Fiona McPhee; Amy K Sheaffer; Jacques Friborg; Dennis Hernandez; Paul Falk; Guangzhi Zhai; Steven Levine; Susan Chaniewski; Fei Yu; Diana Barry; Chaoqun Chen; Min S Lee; Kathy Mosure; Li-Qiang Sun; Michael Sinz; Nicholas A Meanwell; Richard J Colonno; Jay Knipe; Paul Scola
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.